Farber Disease Natural History Study
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/24/2019 |
| Start Date: | November 22, 2017 |
| End Date: | November 2019 |
| Contact: | Alexander Solyom, MD |
| Email: | alex.solyom@enzyvant.com |
| Phone: | +41-78-700-0204 |
Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease
The primary objective of this study is to establish the natural history of Farber disease
(acid ceramidase deficiency) through the collection and analysis of retrospective and
prospective data on patients diagnosed with Farber disease. All patients diagnosed with
Farber disease are eligible, including both those who have and have not undergone
hematopoietic stem cell transplantation (HSCT). Additionally, data and records from deceased
patients will provide valuable retrospective data for this study.
The secondary objective of the study is to establish a set of clinical data, laboratory data
(biomarkers), and functional data potentially useful for:
- Assessing the efficacy of HSCT and the efficacy of potential future therapies (for
example with RVT-801, recombinant human acid ceramidase) in Farber disease
- Characterizing changes in symptoms of patients over time
- Characterizing distinct groups (phenotypes) within the patient population
- Documenting the disease histories of individual patients to serve as intra-subject
control data for those who may enroll in any future clinical studies with therapies for
Farber disease
The exploratory objectives of the study are:
- To explore the relationship between patient disease activity or phenotype and specific
ceramide levels or specific immunologic markers (cytokines/chemokines) in blood
- To evaluate a standardized tool, the Farber Disease Natural History Instrument (FDNI),
to be used for the collection of patient history information, data from clinical,
laboratory, genetic, and functional studies, and data from review of medical records
(acid ceramidase deficiency) through the collection and analysis of retrospective and
prospective data on patients diagnosed with Farber disease. All patients diagnosed with
Farber disease are eligible, including both those who have and have not undergone
hematopoietic stem cell transplantation (HSCT). Additionally, data and records from deceased
patients will provide valuable retrospective data for this study.
The secondary objective of the study is to establish a set of clinical data, laboratory data
(biomarkers), and functional data potentially useful for:
- Assessing the efficacy of HSCT and the efficacy of potential future therapies (for
example with RVT-801, recombinant human acid ceramidase) in Farber disease
- Characterizing changes in symptoms of patients over time
- Characterizing distinct groups (phenotypes) within the patient population
- Documenting the disease histories of individual patients to serve as intra-subject
control data for those who may enroll in any future clinical studies with therapies for
Farber disease
The exploratory objectives of the study are:
- To explore the relationship between patient disease activity or phenotype and specific
ceramide levels or specific immunologic markers (cytokines/chemokines) in blood
- To evaluate a standardized tool, the Farber Disease Natural History Instrument (FDNI),
to be used for the collection of patient history information, data from clinical,
laboratory, genetic, and functional studies, and data from review of medical records
Inclusion Criteria:
- Living or deceased subjects with diagnosis of Farber disease, based on clinical
(typical clinical symptoms) and biochemical and/or genetic criteria, as follows:
- Biochemical: An acid ceramidase activity value in white blood cells, cultured
skin fibroblasts or other biological sources (e.g., plasma) that is less than 30%
of control (normal) values established by the testing laboratory. For deceased
subjects only, storage of ceramide in cells from histopathologic sections is also
adequate to confirm the diagnosis.
- Genetic: Nucleotide changes within both alleles of the acid ceramidase gene
(ASAH1) or cDNA that indicate, through bioinformatics, gene expression studies,
or other methods, a possible loss of function of the acid ceramidase protein.
- Informed consent or assent, for living subjects. For deceased subjects it is the
responsibility of the principal investigator to ensure that the proper requirements
are met according to local laws and regulations.
Exclusion Criteria:
• Current use or history of use in the past 30 days of an investigational agent (with
exception of off-label use of medications).
We found this trial at
3
sites
Washington, District of Columbia 20010
Principal Investigator: Carlos Ferreira Lopez
Phone: 202-476-6812
Click here to add this to my saved trials
787 Bajada Pucará
Córdoba, CP
Córdoba, CP
Principal Investigator: Norberto Guelbert
Phone: (+54 351) 458-6400
Click here to add this to my saved trials
Oakland, California 94609
Principal Investigator: Paul Harmatz
Phone: 510-428-3058
Click here to add this to my saved trials